JP2019514976A - 負荷と放出が正確に制御された術後疼痛用粒子 - Google Patents

負荷と放出が正確に制御された術後疼痛用粒子 Download PDF

Info

Publication number
JP2019514976A
JP2019514976A JP2018558274A JP2018558274A JP2019514976A JP 2019514976 A JP2019514976 A JP 2019514976A JP 2018558274 A JP2018558274 A JP 2018558274A JP 2018558274 A JP2018558274 A JP 2018558274A JP 2019514976 A JP2019514976 A JP 2019514976A
Authority
JP
Japan
Prior art keywords
particles
bupivacaine
weight
dose
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018558274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514976A5 (enExample
Inventor
サヴェージ，ジョン・ロバート
スプレイグ，ジェイコブ・ジェイ
ギャロウェイ，アシュリー
ハード，ジェフリー
リリー，マルキータ・ニコル
ノノヤマ，アキヒサ
ランドルス，エドワード・グラハム
メイナー，ベンジャミン
Original Assignee
リクイディア・テクノロジーズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リクイディア・テクノロジーズ・インコーポレーテッド filed Critical リクイディア・テクノロジーズ・インコーポレーテッド
Publication of JP2019514976A publication Critical patent/JP2019514976A/ja
Publication of JP2019514976A5 publication Critical patent/JP2019514976A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018558274A 2016-05-05 2017-05-05 負荷と放出が正確に制御された術後疼痛用粒子 Pending JP2019514976A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662332015P 2016-05-05 2016-05-05
US62/332,015 2016-05-05
US201662440088P 2016-12-29 2016-12-29
US62/440,088 2016-12-29
US201762443318P 2017-01-06 2017-01-06
US62/443,318 2017-01-06
US201762463206P 2017-02-24 2017-02-24
US62/463,206 2017-02-24
US201762472885P 2017-03-17 2017-03-17
US62/472,885 2017-03-17
PCT/US2017/031397 WO2017193066A1 (en) 2016-05-05 2017-05-05 Precision controlled load and release particles for post-operative pain

Publications (2)

Publication Number Publication Date
JP2019514976A true JP2019514976A (ja) 2019-06-06
JP2019514976A5 JP2019514976A5 (enExample) 2020-06-18

Family

ID=60203445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018558274A Pending JP2019514976A (ja) 2016-05-05 2017-05-05 負荷と放出が正確に制御された術後疼痛用粒子

Country Status (4)

Country Link
US (1) US20190209538A1 (enExample)
EP (1) EP3452031A4 (enExample)
JP (1) JP2019514976A (enExample)
WO (1) WO2017193066A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023073579A (ja) * 2021-11-16 2023-05-26 新田ゼラチン株式会社 生体吸収性粒子

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116669717A (zh) * 2020-08-17 2023-08-29 美国人福制药公司 长效原位成型/胶凝组合物
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
TW202308595A (zh) * 2021-08-13 2023-03-01 大陸商江西濟民可信集團有限公司 一種微球懸液、微粒製劑及其製備方法
WO2025015011A1 (en) * 2023-07-10 2025-01-16 Nevakar Injectables Inc. Bupivacaine compositions and methods
US12648940B2 (en) 2023-09-12 2026-06-09 Fresenius Kabi Austria Gmbh Bupivacaine liquid formulations

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
JPH11511763A (ja) * 1996-06-24 1999-10-12 ユーロ―セルティーク，エス．エイ． 安全な局所麻酔の提供方法
JP2000502728A (ja) * 1996-09-16 2000-03-07 チルドレンズ メディカル センター コーポレーション 局所麻酔を長期化させるための製剤および方法
JP2000511941A (ja) * 1997-07-02 2000-09-12 ユーロ−セルティーク エス．エイ． 関節間隙および身体間隙における持効性麻酔
JP2004521111A (ja) * 2001-01-25 2004-07-15 ユーロ−セルティーク，エス．エイ． 局所麻酔薬および使用法
JP2007511524A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 薬品送達ビヒクル中の賦形剤
JP2009073839A (ja) * 2004-09-17 2009-04-09 Durect Corp 制御されたデリバリーシステム
US20150297730A1 (en) * 2014-04-21 2015-10-22 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CA2611985C (en) * 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
WO2008063204A2 (en) * 2006-01-27 2008-05-29 The University Of North Carolina At Chapel Hill Taggants and methods and systems for fabricating
US20080102123A1 (en) * 2006-10-27 2008-05-01 Schachter Deborah M Self-gelling tunable drug delivery system
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
WO2009132153A2 (en) * 2008-04-22 2009-10-29 Angiotech Pharmaceuticals, Inc. Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same
WO2012075447A2 (en) * 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
US10188772B2 (en) * 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
BR112015015439A2 (pt) * 2012-12-28 2017-07-11 Otsuka Pharma Co Ltd formulação injetável depot, processo para produzir uma formulação injetável depot, e, kit para prevenção ou tratamento de doença renal policística, uso de uma combinação
WO2015164840A1 (en) * 2014-04-24 2015-10-29 Georgia Tech Research Corporation Microneedles and methods of manufacture thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
JPH11511763A (ja) * 1996-06-24 1999-10-12 ユーロ―セルティーク，エス．エイ． 安全な局所麻酔の提供方法
JP2000502728A (ja) * 1996-09-16 2000-03-07 チルドレンズ メディカル センター コーポレーション 局所麻酔を長期化させるための製剤および方法
JP2000511941A (ja) * 1997-07-02 2000-09-12 ユーロ−セルティーク エス．エイ． 関節間隙および身体間隙における持効性麻酔
US20030175357A1 (en) * 1997-07-02 2003-09-18 Paul Goldenhim Prolonged anesthesia in joints and body spaces
JP2004521111A (ja) * 2001-01-25 2004-07-15 ユーロ−セルティーク，エス．エイ． 局所麻酔薬および使用法
JP2007511524A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 薬品送達ビヒクル中の賦形剤
JP2009073839A (ja) * 2004-09-17 2009-04-09 Durect Corp 制御されたデリバリーシステム
US20150297730A1 (en) * 2014-04-21 2015-10-22 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADVANCED DRUG DELIVERY REVIEWS, vol. 64, JPN6021020785, 2012, pages 1021 - 1030, ISSN: 0004519739 *
BIOTECHNOL. J., vol. 6, JPN6021020784, 2011, pages 1477 - 1487, ISSN: 0004519738 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023073579A (ja) * 2021-11-16 2023-05-26 新田ゼラチン株式会社 生体吸収性粒子
JP7768735B2 (ja) 2021-11-16 2025-11-12 新田ゼラチン株式会社 生体吸収性粒子

Also Published As

Publication number Publication date
EP3452031A1 (en) 2019-03-13
US20190209538A1 (en) 2019-07-11
WO2017193066A1 (en) 2017-11-09
EP3452031A4 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
US20190209538A1 (en) Precision Controlled Load and Release Particles for Post-Operative Pain
DK2767292T3 (en) RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
ES2372746T3 (es) Micropartículas de fibrato estabilizadas.
ES2527225T3 (es) Forma de dosificación oral sólida que contiene nanopartículas y proceso para su formulación utilizando gelatina de pescado
US20200069583A1 (en) In situ phase change gel sustained-release system for small molecule drug and preparation method thereof
US20030049320A1 (en) Novel in-situ forming controlled release microcarrier delivery system
TW202027725A (zh) 供藥物之延長投予之液體聚合物輸送系統
TW200812642A (en) Compositions and methods for treating conditions of the nail unit
CN113117092A (zh) 一种非水缓释递药系统
EP2600839A2 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
AU2012201226B2 (en) Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
JP6250005B2 (ja) 制御放出製剤
BRPI0923161B1 (pt) dispositivo implantável de uma peça contendo rilpivirina
Morato et al. Biomaterials for the Sustained Release of Local Anesthetics and Analgesics
AU2017228714A1 (en) Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
JP2003063950A (ja) 固体分散体の製造方法
HK1201437B (en) Sustained local anesthetic composition containing saib
BR102012008240A2 (pt) Composição farmacêutica, micropartícula e método para prevenir ou tratar degeneração macular relacionada com idade
HK1183613A (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
HK1183613B (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211222